Free U.S. shipping on orders over $150
Limitless Labs

Tirzepatide vs Semaglutide: What the Research Shows

Last updated 2026-09-10
On this page+

Tirzepatide and semaglutide are the two most-studied incretin peptides in modern metabolic research, and — unusually for a comparison in this library — they have been tested against each other directly in large randomized trials. SURPASS-2 compared them on glycemic outcomes in type 2 diabetes in 2021 [3], and SURMOUNT-5, published in 2025, compared them on weight reduction in adults with obesity [4]. Both compounds are FDA-approved prescription medicines with extensive phase 3 programs behind them, which makes this one of the few compound pairs where the comparison can rest on head-to-head data rather than cross-trial inference.

This page summarizes what those trials — and each compound's broader evidence base — actually report. It compares trial results, not compounds in the abstract, and it is educational material for researchers, not medical guidance. For full single-compound coverage, see the dedicated articles on tirzepatide and semaglutide.

Side-by-Side Overview

Tirzepatide Semaglutide
Receptor activity Dual agonist: GIP + GLP-1 receptors [1] Single agonist: GLP-1 receptor [2]
Developer Eli Lilly [1] Novo Nordisk [2]
Approval status Mounjaro (type 2 diabetes, 2022); Zepbound (chronic weight management, 2023; obstructive sleep apnea with obesity, 2024) [18][19][20] Ozempic (type 2 diabetes, 2017); Rybelsus (oral tablet, 2019); Wegovy (chronic weight management, 2021) [2]
Head-to-head: weight (SURMOUNT-5) Mean −20.2% at 72 weeks; 31.6% of participants reached ≥25% reduction [4] Mean −13.7% at 72 weeks; 16.1% reached ≥25% reduction [4]
Head-to-head: glycemic (SURPASS-2) HbA1c −2.01 to −2.30 points by dose; weight −7.6 to −11.2 kg [3] HbA1c −1.86 points; weight −5.7 kg — at the 1 mg dose, lower than doses studied since [3]
Key mono-trial weight result SURMOUNT-1: −20.9% at 72 weeks (highest dose) vs −3.1% placebo [5] STEP 1: −14.9% at 68 weeks (2.4 mg) vs −2.4% placebo [6]
CV outcomes data SURPASS-CVOT: noninferior to dulaglutide (active comparator) in type 2 diabetes; superiority narrowly missed [11]; placebo-controlled obesity trial (SURMOUNT-MMO) ongoing to ~2027 [21] SUSTAIN-6: fewer major CV events vs placebo in type 2 diabetes [9]; SELECT: ~20% MACE reduction vs placebo in obesity without diabetes [10]
Evidence depth Approved since 2022; outcomes data expanding — sleep apnea, heart failure (HFpEF), CVOT published 2025 [11][12][13] Approved since 2017; completed outcome trials span cardiovascular, kidney, liver, and peripheral artery disease [9][10][14][16][17]

Mechanism: What the GIP Addition Changes

Semaglutide is a long-acting analogue of GLP-1, engineered by Novo Nordisk with two amino-acid substitutions and a fatty di-acid chain that extend its half-life through albumin binding [2]. Activating the GLP-1 receptor enhances glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, slows gastric emptying, and reduces appetite through central pathways [2].

Tirzepatide keeps all of that GLP-1 activity but adds a second target. It is a 39-amino-acid peptide built on the backbone of native GIP — the other major incretin hormone — and modified so it also activates the GLP-1 receptor. Its receptor profile is intentionally imbalanced: GIP-receptor affinity comparable to native GIP, GLP-1-receptor affinity roughly fivefold weaker than native GLP-1 [1]. The working hypothesis in the literature is that GIP agonism adds to GLP-1-mediated effects on appetite and insulin secretion — possibly through adipose-tissue function and central signaling — while improving the tolerability ceiling, allowing more total incretin activity for a given level of gastrointestinal side effects [1]. How much of the observed clinical difference is attributable to GIP signaling versus tirzepatide's pharmacokinetics and biased GLP-1 signaling remains an open mechanistic question [1].

The Head-to-Head Trials

SURMOUNT-5: weight reduction in obesity

SURMOUNT-5 was the first large randomized head-to-head between the two compounds in obesity. In 751 adults with obesity but without diabetes, treated for 72 weeks at maximum tolerated doses of each medicine, participants receiving tirzepatide experienced a mean weight reduction of 20.2%, versus 13.7% among those receiving semaglutide. At the highest threshold reported, 31.6% of tirzepatide participants achieved at least 25% weight reduction, versus 16.1% with semaglutide [4]. Because both arms were titrated to maximum tolerated doses, this trial does not carry the dose-mismatch caveat that applies to SURPASS-2.

SURPASS-2: glycemic outcomes in type 2 diabetes

SURPASS-2 compared tirzepatide with semaglutide 1 mg in 1,879 adults with type 2 diabetes on metformin over 40 weeks. HbA1c fell by 2.01, 2.24, and 2.30 percentage points at tirzepatide 5 mg, 10 mg, and 15 mg respectively, versus 1.86 points with semaglutide; body-weight reductions were 7.6, 9.3, and 11.2 kg versus 5.7 kg. All three tirzepatide doses met the trial's prespecified superiority criteria against semaglutide 1 mg on both measures [3].

The dose caveat matters: 1 mg was the highest approved semaglutide dose for type 2 diabetes when SURPASS-2 was designed, and semaglutide has since been studied and used at higher doses (2 mg in diabetes, 2.4 mg in weight management). SURPASS-2 therefore compares tirzepatide's full dose range against a semaglutide dose below its current ceiling — a limitation the head-to-head SURMOUNT-5 design later avoided [3][4].

One pattern holds across both compounds' separate programs: participants with type 2 diabetes lost somewhat less weight than those without. In SURMOUNT-2 (obesity plus type 2 diabetes), tirzepatide produced mean reductions of 12.8–14.7% versus 3.2% with placebo [7], and STEP 2 reported the same directional gap for semaglutide relative to STEP 1's non-diabetic population [8].

Both compounds showed the same tolerability signature across these trials: dose-related gastrointestinal adverse events — nausea, diarrhea, vomiting, constipation — concentrated during dose escalation, and the most common reason for discontinuation in each program [3][4][6].

Selected Semaglutide Outcomes

  • Placebo-controlled cardiovascular outcomes — including in obesity without diabetes. SUSTAIN-6 reported fewer major adverse cardiovascular events versus placebo in high-risk type 2 diabetes (6.6% vs 8.9% over ~2 years) [9]. SELECT then extended the question to 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes, reporting an approximately 20% reduction in major cardiovascular events versus placebo — the first cardiovascular outcomes benefit shown for a weight-management pharmacotherapy in a non-diabetic population [10]. Tirzepatide's equivalent placebo-controlled obesity trial, SURMOUNT-MMO, is not expected to complete until around 2027 [21].
  • Kidney outcomes. FLOW randomized 3,533 patients with type 2 diabetes and chronic kidney disease and was stopped early for efficacy: major kidney disease events were 24% lower with semaglutide versus placebo [14]. No comparable dedicated kidney-outcomes trial has read out for tirzepatide.
  • An oral formulation. The PIONEER program established oral semaglutide, with PIONEER 6 confirming cardiovascular safety [15] and the 2025 SOUL trial reporting a 14% reduction in major cardiovascular events with the oral form in high-risk type 2 diabetes [16]. Tirzepatide exists only as an injectable.
  • Liver disease. In the phase 3 ESSENCE trial in metabolic dysfunction–associated steatohepatitis (MASH), 62.9% of semaglutide participants achieved resolution of steatohepatitis without worsening fibrosis versus 34.3% on placebo at the 72-week interim analysis [17].

Selected Tirzepatide Outcomes

  • Obstructive sleep apnea. The two SURMOUNT-OSA trials reported apnea–hypopnea index reductions of 25.3 and 29.3 events per hour versus 5.3 and 5.5 with placebo, leading to Zepbound's December 2024 approval as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity — an indication semaglutide does not hold [12][20].
  • Heart failure with preserved ejection fraction. In SUMMIT, participants with HFpEF and obesity receiving tirzepatide had a 38% lower relative risk of cardiovascular death or worsening heart failure versus placebo (9.9% vs 15.3% over a median 104 weeks), though HFpEF is not an approved indication [13].
  • A completed CVOT against an active comparator. SURPASS-CVOT randomized more than 13,000 high-risk patients with type 2 diabetes to tirzepatide or dulaglutide — a GLP-1 agonist with proven cardiovascular efficacy — rather than placebo. Tirzepatide was noninferior on major adverse cardiovascular events (12.2% vs 13.1%), without establishing superiority on the primary endpoint, with favorable secondary metabolic findings [11]. An active-comparator noninferiority trial answers a different question from a placebo-controlled trial. SUMMIT provides placebo-controlled evidence in HFpEF and obesity [13]; the broader obesity morbidity/mortality question is being studied in SURMOUNT-MMO [21].

Reading the Comparison Honestly

SURPASS-2 reported larger mean HbA1c and weight reductions with tirzepatide than with semaglutide 1 mg in type 2 diabetes [3]. SURMOUNT-5 addressed weight reduction in adults without diabetes, using maximum tolerated doses of each compound [4]; it should not be presented as a second diabetes glycemic-efficacy trial. But the two evidence bases are at different stages of maturity: semaglutide has roughly a five-year head start, and the cited semaglutide trials include dedicated kidney outcomes, phase 3 liver histology, and cardiovascular outcomes in obesity without diabetes [9][10][14][16][17]. Those endpoints and populations differ from the tirzepatide studies summarized here. Several of the biggest open questions — tirzepatide's placebo-controlled cardiovascular effect in obesity, long-term maintenance strategies for both compounds, and the mechanistic contribution of GIP agonism — are the subject of ongoing trials and active debate rather than settled findings [1][11][21].

References

  1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009. PMID: 30473097
  2. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. DOI: 10.1021/acs.jmedchem.5b00726
  3. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519. PMID: 34170647
  4. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394. PMID: 40353578
  5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. PMID: 35658024
  6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183 · PubMed 33567185
  7. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626. doi:10.1016/S0140-6736(23)01200-X. PMID: 37385275
  8. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971–984. PubMed 33667417
  9. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834–1844. PubMed 27633186
  10. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221–2232. DOI: 10.1056/NEJMoa2307563 · PubMed 37952131
  11. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409–2420. doi:10.1056/NEJMoa2505928. PMID: 41406444
  12. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193–1205. doi:10.1056/NEJMoa2404881. PMID: 38912654
  13. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427–437. doi:10.1056/NEJMoa2410027. PMID: 39555826
  14. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391(2):109–121. DOI: 10.1056/NEJMoa2403347 · PubMed 38785209
  15. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). N Engl J Med. 2019;381:841–851. DOI: 10.1056/NEJMoa1901118
  16. McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL). N Engl J Med 2025. DOI: 10.1056/NEJMoa2501006 · PubMed 40162642
  17. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21):2089–2099. DOI: 10.1056/NEJMoa2413258
  18. U.S. Food and Drug Administration. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes (Mounjaro). Press release, May 13, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
  19. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound). Press release, November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  20. Eli Lilly and Company. FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. Press release, December 20, 2024. https://www.prnewswire.com/news-releases/fda-approves-zepbound-tirzepatide-as-the-first-and-only-prescription-medicine-for-moderate-to-severe-obstructive-sleep-apnea-in-adults-with-obesity-302337722.html
  21. ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). NCT05556512. https://clinicaltrials.gov/study/NCT05556512

This article summarizes published scientific literature for educational purposes only. Both compounds discussed are FDA-approved prescription medicines — tirzepatide as Mounjaro and Zepbound, semaglutide as Ozempic, Rybelsus, and Wegovy — available only through licensed pharmacies under medical supervision. Research-grade material sold as a laboratory reference standard is a separate category that is not a drug product and is not for human use. Nothing here constitutes medical advice, and no statement about research materials has been evaluated by the FDA.

Disclaimer: Research materials supplied by Limitless Labs are intended strictly for in-vitro research and laboratory use only. They are not intended for human or animal consumption, therapeutic use, or any form of self-administration. They are not approved medicines. Where this library discusses an approved pharmaceutical, that product is distinct from research materials sold by Limitless Labs. This page is an educational summary of published research and is not medical advice. These statements have not been evaluated by the Food and Drug Administration.

Get research updates

Subscribe to the Limitless Labs newsletter for research insights and product updates. You can unsubscribe at any time.